リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Case report: Severe non-pigmenting fixed drug eruption showing general symptoms caused by chondroitin sulfate sodium」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Case report: Severe non-pigmenting fixed drug eruption showing general symptoms caused by chondroitin sulfate sodium

Otsuka, Haruhiko Fukumoto, Takeshi Oka, Masahiro Nishigori, Chikako 神戸大学

2022.10.28

概要

Non-pigmenting fixed drug eruption (NPFDE) is a subtype of fixed drug eruption (FDE) in which repeated eruptions occur at the same site. Clinically, NPFDE disappears without pigmentation changes; however, it sometimes causes fever or arthralgia. Its histopathological characteristics reportedly include infiltrations of CD8-positive T cells with a paucity of melanocytes as compared to FDE. We present the first case of severe NPFDE exhibiting general symptoms caused by chondroitin sulfate sodium. The patient was a 44-year-old man. Intravenous injection of chondroitin sulfate sodium caused erythema in the affected area. A histopathological examination of the biopsy tissue revealed infiltration of CD3-positive lymphocytes (both CD4-positive and CD8-positive lymphocytes) into the epidermis, minimal liquefaction degeneration in the basal layer of the epidermis, and few dermal melanophages, which may be responsible for non-pigmentation.

参考文献

1. Fukuda R, Ouchi T, Hirai I, Funakoshi T, Honda A, Tanese K, et al. Non-pigmenting fixed drug eruption with mixed features of acute generalized exanthematous pustulosis induced by pseudoephedrine: a case report. Contact Dermatitis. (2017) 77:123–6. doi: 10.1111/cod.12754

2. Mizukawa Y, Shiohara T. Nonpigmenting fixed drug eruption as a possible abortive variant of toxic epidermal necrolysis: immunohistochemical and serum cytokine analyses. Clin Exp Dermatol. (2010) 35:493–7. doi: 10.1111/j.1365-2230. 2009.03622.x

3. Shiohara T, Ushigome Y, Kano Y, Takahashi R. Crucial role of viral reactivation in the development of severe drug eruptions: a comprehensive review. Clin Rev Allergy Immunol. (2015) 49:192–202. doi: 10.1007/s12016-014-8421-3

4. Andrade P, Brinca A, Goncalo M. Patch testing in fixed drug eruptions–a 20- year review. Contact Dermatitis. (2011) 65:195–201. doi: 10.1111/j.1600-0536.2011. 01946.x

5. Cheraghlou S, Levy LL. Fixed drug eruptions, bullous drug eruptions, and lichenoid drug eruptions. Clin Dermatol. (2020) 38:679–92.

6. Woodruff CM, Botto N. The role of patch testing in evaluating delayed hypersensitivity reactions to medications. Clin Rev Allergy Immunol. (2022) 62:548–61.

7. Schiraldi C, Cimini D, De Rosa M. Production of chondroitin sulfate and chondroitin. Appl Microbiol Biotechnol. (2010) 87:1209–20.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文

一発検索!

この論文の関連論文を見る